Check your chocolate. Several companies announce candy and snacks recalls
Be careful when buying those sweets for this Valentine's Day.
A couple of chocolate manufacturers recently issued recalls for their products, mostly sold outside of Indiana.
On Jan. 29, United Natural Trading announced it was voluntarily recalling its Fresh Direct Dark Chocolate Covered Pretzels due to undeclared milk ingredients.
'People who have an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reaction if they consume this product,' the Edison, New Jersey-based company said in the announcement.
The affected products are from Lot Number 24353 with a Best By Date of 06/30/2025 and a UPC# 811102026276.
The products were shipped via online sales via a third-party vendor site in limited quantities to the Connecticut, New Jersey, and New York areas. The lot numbers are printed on the back of each retail packaging.
Consumers who have any remaining product from the lot should discard it and keep online receipts or packaging that reflects lot numbers or any other proof of purchase they have for a refund.
For more information, contact the company at 732-650-9905 from 9 a.m. to 5 p.m. Eastern Monday through Friday.
On. Jan. 22, the U.S. Food and Drug Administration (FDA) elevated a recall of some Cal Yee Farm chocolate products to its most serious level, Class I, for some products — Dark Chocolate Almonds, Dark Chocolate Apricots and Dark Chocolate Walnuts — that contain milk not listed in the ingredients, according to the New York Post.
An FDA Class I recall involves a situation in which there is a reasonable probability that the use of or exposure to the product will cause serious adverse health consequences or death.
The items were part of a December 2024 voluntary recall of products with the undisclosed presence of milk, soy, wheat, sesame, FD&C #6 and almonds.
The Suisun Valley, California-based company initially announced the recall of chocolate and yogurt-covered snacks, trail mix and butter toffee on Dec. 12, 2024, saying people with an allergy or severe sensitivity to those ingredients run the risk of a serious or life-threatening allergic reaction if they consume those products. The recall came after an FDA inspection of its facility.
Dark Chocolate Walnuts
Dark Chocolate Raisins
Dark Chocolate Almonds
Yogurt Coated Almonds
Dark Chocolate Apricots
Tropical Trail Mix
Butter Toffee
Almonds (sold under Cal Yee's and Boa Vista Orchards brands)
Mango with Chili
Hot Cajun Sesame Sticks
New Orleans Hot Mix
Fruit Basket 2909
Fruit Basket 2921
The products were distributed in California, Arizona, Virginia, New Mexico, Texas, Tennessee, Oregon, Ohio and Pennsylvania through the Cal Yee Farm retail store at 5158 Clayton Rd. in Suisun Valley, California, and online at calyeefarm.com.
Butter Toffee Almonds were also sold through the Boa Vista Orchards retail store at 2952 Carson Rd. in Placerville, California.
The Cal Yee- and Cal Yee Farm-branded items were packaged in clear plastic zippered pouches in either eight-ounce, one-pound, two-pound and five-pound sizes with a bright yellow label identifying the product in front of the pouch.
Dark Chocolate Apricots were packaged in two types of plastic containers with a white or yellow label identifying the product.
Fruit Baskets were packaged in a basket with a yellow label identifying the product on the back of the basket.
Boa Vista Orchard-branded Butter Toffee Almonds were packaged in a six-ounce clear plastic zippered pouch with a white label identifying the product.
Customers with milk, soy, wheat, sesame, FD&C #6 and almonds allergies or sensitivities who have purchased the affected products should not consume the product and should dispose of them or return them for a full refund.
For more information, contact 707-425-5327 or mariatmail03@gmail.com from 8 a.m. to 4:30 p.m. Pacific Monday through Friday.
Those announcements followed the Jan. 21 recall of D. Coluccio & Sons' Colussi Cantuccini Chocolate Drops chocolate chip cookies due to undeclared potential almond content.
People who have allergies to tree nuts (almonds) run the risk of serious or life-threatening allergic reactions if they consume these products, the company said.
The cookies were distributed nationwide via retail stores and mail orders, packaged in 10.58-ounce blue bags with UPC 8002590006020, marked with lot numbers 3540152 BBD 15-01-2025 and L354150 BBD 29-05-2025 on the back of the bag.
Consumers who have purchased the affected Colussi Cantuccini Chocolate Drops cookies packages are urged to return them to the place of purchase for a full refund. For more information, contact the company at 718-436-6700 from 8 a.m. to 5 p.m. Eastern or via email at customerservice@dcoluccioandsons.com.
This article originally appeared on Indianapolis Star: Chocolate recalls: Several companies warn about products. What to know
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
42 minutes ago
- Business Wire
HekaBio, Japan-based Biopharma and MedTech Platform, Enters Strategic Partnership with Alfresa Holdings Corporation
TOKYO--(BUSINESS WIRE)--HekaBio K.K. (Headquarters: Chuo-ku, Tokyo; President & CEO: Robert E. Claar; hereinafter 'HekaBio') today announced the signing of a strategic partnership agreement with Alfresa Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; Representative Director & President: Ryuji Arakawa; hereinafter 'Alfresa Holdings'), the leading pharmaceutical wholesaler group in Japan. As part of this agreement, Alfresa Holdings has also made a capital investment in HekaBio. The partnership aims to accelerate the commercialization of innovative medical products in Japan. HekaBio, Japan-based Biopharma and MedTech Platform, Enters Strategic Partnership with Alfresa Holdings Corporation -- Accelerating Access to Innovative Therapies in Japan through Alfresa Group's 'Total Supply Chain Service'-- Share Background and Purpose In recent years, Japan has implemented policy reforms to address the growing access gap, where innovative therapies approved overseas are slow to come to the Japanese market. In response to these developments, HekaBio has focused on introducing cutting-edge pharmaceuticals, medical devices, and regenerative medicine products from global markets into Japan and the Asia-Pacific markets. Leveraging a proprietary global network and partnership model, HekaBio evaluates over 200 assets annually across oncology, cardiology and CNS, and supports end-to-end commercialization from licensing to clinical and regulatory development, manufacturing and sales. This partnership with Alfresa Group will enable HekaBio to advance and expand its portfolio and impact, particularly in CNS and regenerative medicine where Alfresa Group has strengths in manufacturing and in sales, including various other aspects of sales-related operations across the supply chain. Outlook Through this partnership, HekaBio and Alfresa Group aim to accelerate the introduction of high-impact, potential blockbuster therapies into the Japanese market, expanding treatment options for patients. The companies also plan to explore commercialization strategies across the Asia-Pacific region and beyond. About HekaBio HekaBio is a Japan-based, asset-light healthcare platform that accelerates patient access to global medicines and MedTech across Asia-Pacific. HekaBio reviews over 200 assets annually to in-license a select few, focusing on early-stage, de-risked opportunities in CNS, oncology, and healthy longevity. HekaBio synchronizes U.S. and Japan development timelines and leverages strategic partnerships to optimize commercial success. Japan, the world's third-largest healthcare market, serves as its launchpad for regional expansion. To learn more about HekaBio's mission and portfolio, visit About Alfresa Holdings Alfresa Holdings is the holding company for the Alfresa Group, which operates businesses ranging from the development, manufacture, and distribution of pharmaceuticals to the operation of dispensing pharmacies and is the top corporate group in Japan in terms of ethical pharmaceuticals wholesaling, with consolidated net sales exceeding ¥2.9 trillion in the fiscal year ended March 31, 2025. Guided by its corporate philosophy, 'we create and deliver a fresh life for all,' the entire Group supports supply chains for pharmaceuticals and other products, a form of social infrastructure underpinning Japanese healthcare, contributing to a wide range of medical needs. For more information:
Associated Press
6 hours ago
- Associated Press
Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients
INCHEON, South Korea, June 15, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), in a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection. The additional presentation is approved for the treatment of pediatric patients aged 6 to 17 years, weighing less than 60kg, with plaque psoriasis (PsO) or psoriatic arthritis (PsA).[1] With this approval, STEQEYMA now offers all dosage forms and strengths of its reference product, providing flexibility to meet physicians' clinical needs while supporting treatment continuity for patients. In December 2024, the FDA approved STEQEYMA in 45mg/0.5mL and 90mg/mL solutions in a single-dose prefilled syringe for subcutaneous injection, and 130mg/26mL in a single-dose vial for intravenous infusion in adult and pediatric patients 6 years and older with plaque psoriasis and psoriatic arthritis, as well as adult patients with Crohn's disease and ulcerative colitis. 'Managing inflammatory diseases in pediatric patients can be particularly complex,' said Hetal Patel, PharmD MBA, Vice President of Medical Affairs at Celltrion USA. 'The new dosage form and strength of STEQEYMA allow us to better meet the specific needs of young patients, giving physicians a valuable treatment option with flexibility, supported by a well-established safety and efficacy profile.' 'We are proud to offer a new presentation of STEQEYMA that aligns with the indications of the reference product,' said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. 'This approval reinforces our commitment to broadening access for all patient populations, including children aged 6 years and older living with chronic inflammatory conditions. As a company with a strong legacy in immunology, we are dedicated to ensuring broader access and flexibility in care for patients of all ages.' The FDA approval of STEQEYMA was based on the totality of evidence, including the results from a phase III study in adults with moderate to severe plaque psoriasis, in which the primary endpoint was the rate of change in the Psoriasis Area and Severity Index (PASI) for skin symptoms. The clinical results demonstrated that STEQEYMA and its reference product, ustekinumab, are highly similar, and have no clinically meaningful differences in terms of safety and efficacy.[2],[3] The FDA has granted STEQEYMA full interchangeability with STELARA across all indications of STELARA, following the expiration of exclusivity for the first interchangeable biosimilar on April 30, 2025. Notes to Editors: About STEQEYMA® (ustekinumab-stba) STEQEYMA®, formerly known as CT-P43, is a human IL-12 and -23 antagonist indicated for multiple immune-mediated diseases. It encompasses all indications approved for the STELARA® reference product, including psoriasis (PsO), psoriatic arthritis (PsA), Crohn's disease (CD), ulcerative colitis (UC) in adults, and PsO and PsA in pediatric patients 6 years of age and older. STEQEYMA is available in both subcutaneous and intravenous formulations. The subcutaneous injection comes in 45mg/0.5 mL or 90mg/1 mL solution in a single-dose, prefilled syringe and 45mg/0.5mL solution in a single-dose vial. The intravenous infusion is provided as a 130mg/26 mL (5mg/mL) solution in a single-dose vial. INDICATIONS STEQEYMA® (ustekinumab-stba) is indicated for the treatment of: IMPORTANT SAFETY INFORMATION For more information, see Full Prescribing Information. About Celltrion, Inc. Celltrion is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world's first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website and stay updated with our latest news and events on our social media: LinkedIn, Instagram, X, and Facebook. About Celltrion USA Celltrion USA is Celltrion's U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion's FDA-approved biosimilar products in immunology, oncology, hematology, and endocrinology include: INFLECTRA® (infliximab-dyyb), TRUXIMA® (rituximab-abbs), HERZUMA® (trastuzumab-pkrb), VEGZELMA® (bevacizumab-adcd), YUFLYMA®(adalimumab-aaty), AVTOZMA® (tocilizumab-anho), STEQEYMA® (ustekinumab-stba), STOBOCLO® (denosumab-bmwo), OSENVELT® (denosumab-bmwo) and OMLYCLO® (omalizumab-igec), as well as the novel biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information, please visit and stay updated with our latest news and events on our social media: LinkedIn. FORWARD-LOOKING STATEMENT Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion, Inc. and its subsidiaries that may constitute forward-looking statements under pertinent securities laws. This press release contains forward looking statements. These statements may be also identified by words such as 'prepares', 'hopes to', 'upcoming', 'plans to', 'aims to', 'to be launched', 'is preparing', 'once gained', 'could', 'with the aim of', 'may', 'once identified', 'will', 'working towards', 'is due', 'become available', 'has potential to', 'anticipate' the negative of these words or such other variations thereon or comparable terminology. In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion, Inc. and its subsidiaries' management, of which many are beyond its control. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company's business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements. Celltrion, Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. Trademarks STELARA® is a registered trademark of Johnson & Johnson. STEQEYMA® is a registered trademark of Celltrion, Inc., used under license. References For further information please contact: Andria Arena [email protected] +1 516-578-0057 View original content to download multimedia: SOURCE Celltrion
Business Insider
6 hours ago
- Business Insider
I bring healthcare to people's homes in Singapore. AI is changing home care, but it can't replace clinicians.
This as-told-to essay is based on a conversation with Dr. Shravan Verma, the cofounder and CEO of Speedoc, a Singapore-based health tech startup. This interview has been edited for length and clarity. As someone who has worked in both tertiary hospitals as well as some underserved environments, I saw the opportunity to create a virtual hospital that brings healthcare directly to where patients are, starting with their homes. Why should access to hospital-grade care be dependent on geography or infrastructure? The home will become the new center of care, and AI will be the invisible infrastructure enabling this shift. With AI software becoming more sophisticated and AI-enabled hardware becoming more accessible, care will become more personalized. I see the future of home care as a hybrid, with AI-enabled self-care tools integrated into regulated, human-involved systems. Singapore and the region are more ready than we think. In Singapore, we're already seeing strong policy alignment and public trust in digital systems. Even the patient mindset is maturing around receiving care outside traditional hospitals. Embedded AI AI is already a foundational layer of our operations. Our command center uses AI to triage patient cases, optimize our logistics for clinician dispatch, and even anticipate escalation risks. For example, AI models continuously analyze data from devices like pulse oximeters, BP monitors, or even passive sensors. If a patient's vitals begin trending dangerously, clinicians are alerted before deterioration sets in. We've prevented emergency room visits this way. The next phase is using AI for predictive care, orchestration, preempting deterioration in chronic patients, automating routine follow-ups, and eventually building an AI copilot for our clinicians. Clinicians expect systems to support and not slow down their work. Our nurses and doctors are asking for tools that reduce admin burden, triage smarter, and give them more actionable insights. Patients, too, are increasingly comfortable with these digital touchpoints, but they do want these to feel personalized and intelligent. Clinicians will be transformed, not replaced, by AI AI will transform but not replace the clinician role, especially in home settings. Their role becomes more relational as AI simplifies documentation and supports better decision-making. AI can't replicate the presence, empathy, and nuanced judgment in uncertain or complex conditions. It can't speak with family and understand what's best for the patient. AI can tell you — worst case — you're having a heart attack, but then what do you do about it? I know the diagnosis of a heart attack, but I need to be sent immediately to a hospital, make sure that I get stented, and get the catheterization, which is still very human-driven. Somebody also has to ensure continuity, ensure the administration of treatments and follow-ups, and ensure that the patients are improving as they're supposed to. Many of the conditions we treat at home also require IV drips, IV antibiotics, blood tests, and urine tests. Lead with outcomes, not AI Chatbots and AI tools can handle the first mile of care, but they must escalate to qualified professionals when needed. We need to be vigilant about bias in training data and sometimes a lack of contextual nuances in understanding what a patient's condition is. One of the key challenges with AI is confabulation, which is AI coming up with analysis or data that didn't exist for the patient. Governance, transparency, and auditability must be baked into every AI deployment. When it comes to AI-driven home care, the key is not to lead with AI but with outcomes and convenience. Patients don't really ask, "Is this AI?" They ask, "Is this faster, safer, more personalized?" When AI helps a patient get triaged within minutes or enables a nurse to show up at the right time with the right medication, that builds confidence. The real unlock is making sure AI remains transparent, empathetic, and always augments, not replaces, the human touch.
